Why Lilly and NVIDIA Are Going All In on AI Discovery

Eli Lilly and NVIDIA launch a $1B AI lab to weave artificial intelligence into the earliest stages of drug research

23 Jan 2026

Eli Lilly and Nvidia have agreed to create a joint artificial intelligence lab with funding of up to $1bn over five years, highlighting how central AI is becoming to pharmaceutical research strategies.

Announced at the 2026 J.P. Morgan Healthcare Conference, the partnership will focus on the earliest stages of drug discovery, where scientific uncertainty is highest and failure rates are greatest. The lab will be based in the San Francisco Bay Area and will bring together Lilly’s biologists and Nvidia’s AI engineers in a shared physical location.

The aim is to embed AI directly into discovery workflows rather than using it in limited pilot projects. The partners plan to combine computational modelling with laboratory experiments, allowing insights from data and biology to be developed in parallel.

The initiative will build on Lilly’s existing Nvidia-powered AI supercomputer and use platforms such as Nvidia’s BioNeMo, which is designed to train large-scale biological models. Lilly said the approach should help researchers generate more reliable insights earlier in the research process and improve how potential drug targets are assessed.

Drug development typically takes more than a decade, with most experimental medicines failing long before reaching patients. Many large pharmaceutical companies now see early discovery as the stage where better use of data and computing could have the greatest impact, even if AI does not dramatically shorten overall timelines.

The partnership reflects a broader shift in the industry towards treating AI as core infrastructure rather than a standalone tool. Nvidia supplies the computing architecture needed to analyse complex biological data at scale, while Lilly contributes disease expertise and the ability to move projects from discovery into clinical development.

The collaboration could have wider implications for the sector. As more drugmakers pursue similar models, demand is likely to rise for AI-enabled laboratory equipment, data platforms and automation systems, benefiting suppliers positioned around AI-ready research.

Significant challenges remain. Companies must manage sensitive data, validate AI-generated insights and adapt to evolving regulatory expectations. Whether such a tightly integrated model can remain flexible and productive over time is still uncertain.

Even so, the scale of the investment raises expectations. If successful, the lab could shape how future partnerships are designed and how aggressively pharmaceutical groups commit capital to AI-driven discovery.